



Article scientifique

Article

2018

Published version

Open Access

This is the published version of the publication, made available in accordance with the publisher's policy.

Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study

Orasch, Christina; Mertz, Dominik; Garbino, Jorge; Van Delden, Christian; Emonet, Stéphane; Schrenzel, Jacques; Zimmerli, Stefan; Damonti, Lauro; Mühlethaler, Konrad; Imhof, Alexander; Ruef, Christian; Fehr, Jan; Zbinden, Reinhard; Boggian, Katia [and 12 more]

How to cite

ORASCH, Christina et al. Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. In: Journal of Infection, 2018, vol. 76, n° 5, p. 489–495. doi: 10.1016/j.jinf.2017.12.018

This publication URL: <https://archive-ouverte.unige.ch/unige:127252>

Publication DOI: [10.1016/j.jinf.2017.12.018](https://doi.org/10.1016/j.jinf.2017.12.018)



Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study

Christina Orasch ^{a,b,c,*}, Dominik Mertz ^{d,e}, Jorge Garbino ^f, Christian van Delden ^f, Stephane Emonet ^f, Jacques Schrenzel ^g, Stefan Zimmerli ^h, Lauro Damonti ^{a,h}, Konrad Mühlethaler ^h, Alexander Imhof ^{i,j}, Christian Ruef ^{k,l}, Jan Fehr ^k, Reinhard Zbinden ^m, Katia Boggian ⁿ, Thomas Bruderer ^o, Ursula Flückiger ^{p,c}, Anna Conen ^{c,q}, Nina Khanna ^c, Reno Frei ^r, Thomas Bregenzer ^{q,s}, Frédéric Lamoth ^{a,t}, Véronique Erard ^{a,u}, Pierre-Yves Bochud ^a, Thierry Calandra ^a, Jacques Bille ^{t,1}, Oscar Marchetti ^{a,v,**,1} the Fungal Infection Network of Switzerland (FUNGINOS) ²

^a Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland

^b Infectious Diseases and Hospital Epidemiology, Hirslanden Klinik St. Anna, Lucerne, Switzerland

^c Division of Infectious Diseases and Hospital Epidemiology, Basel University Hospital, Basel, Switzerland

^d Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, Canada

^e Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

^f Infectious Diseases Service, Department of Medical Specialties, Geneva University Hospitals, Geneva, Switzerland

^g Bacteriology Laboratory, Service of Laboratory Medicine, Department of Genetics & Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland

^h Department of Infectious Diseases, Bern University Hospital (Inselspital), and Institute for Infectious Diseases, University of Bern, Bern, Switzerland

ⁱ Department of Medicine, Zurich University Hospital, Zurich

^j Department of Medicine, Oberrhein Hospital, Langenthal, Switzerland

^k Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

^l Hirslanden Klinik, Zurich, Switzerland

^m Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland

ⁿ Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital, Sankt Gallen, Switzerland

^o Department of Bacteriology, Mycology and Parasitology, Center of Laboratory Medicine, Cantonal Hospital, Sankt Gallen, Switzerland

^p Hirslanden Klinik, Aarau, Switzerland

^q Division of Infectious Diseases and Hospital Hygiene, Kantonsspital, Aarau, Switzerland

^r Division of Clinical Microbiology, Laboratory Medicine, Basel University Hospital, Basel, Switzerland

^s Klinik für Innere Medizin, Spital Lachen AG, Lachen, Switzerland

^t Institute of Microbiology, Department of Laboratories, Lausanne University Hospital, Lausanne, Switzerland

^u Clinique de Médecine, HFR-Fribourg Hospital, Fribourg, Switzerland

^v Department of Medicine, Ensemble Hospitalier de la Côte, Morges, Switzerland

ARTICLE INFO

Article history:

Accepted 11 December 2017

Available online 31 January 2018

Keywords:

Candidemia
Breakthrough
Fluconazole
Susceptibility
Candida
Species
FUNGINOS

ABSTRACT

Objectives: Breakthrough candidemia (BTC) on fluconazole was associated with non-susceptible *Candida* spp. and increased mortality. This nationwide FUNGINOS study analyzed clinical and mycological BTC characteristics.

Methods: A 3-year prospective study was conducted in 567 consecutive candidemias. Species identification and antifungal susceptibility testing (CLSI) were performed in the FUNGINOS reference laboratory. Data were analyzed according to STROBE criteria.

Results: 43/576 (8%) BTC occurred: 37/43 (86%) on fluconazole (28 prophylaxis, median 200 mg/day). 21% BTC vs. 23% non-BTC presented severe sepsis/septic shock. Overall mortality was 34% vs. 32%. BTC was associated with gastrointestinal mucositis (multivariate OR 5.25, 95%CI 2.23–12.40, $p < 0.001$) and graft-versus-host-disease (6.25, 1.00–38.87, $p = 0.05$), immunosuppression (2.42, 1.03–5.68, $p = 0.043$), and parenteral nutrition (2.87, 1.44–5.71, $p = 0.003$). Non-*albicans Candida* were isolated in 58% BTC vs.

* Corresponding author: Infectious Diseases and Hospital Epidemiology, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, CH-6006 Luzern, Switzerland

** Corresponding author: Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.

E-mail addresses: Christina.Orasch@hirslanden.ch (C. Orasch), Oscar.Marchetti@chuv.ch (O. Marchetti).

¹J.B. and O.M. have equal contributions.

²The Clinical and Microbiology Laboratory Investigators of the FUNGINOS network are listed in the Appendix.

35% non-BTC ($p = 0.005$). 63% of 16 BTC occurring after 10-day fluconazole were non-susceptible (*Candida glabrata*, *Candida krusei*, *Candida norvegensis*) vs. 19% of 21 BTC (*C. glabrata*) following shorter exposure (7.10, 1.60–31.30, $p = 0.007$). Median fluconazole MIC was 4 mg/l vs. 0.25 mg/l ($p < 0.001$). Ten-day fluconazole exposure predicted non-susceptible BTC with 73% accuracy.

Conclusions: Outcomes of BTC and non-BTC were similar. Fluconazole non-susceptible BTC occurred in three out of four cases after prolonged low-dose prophylaxis. This implies reassessment of prophylaxis duration and rapid de-escalation of empirical therapy in BTC after short fluconazole exposure.

© 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Introduction

Candida spp. belong to the top ten bloodstream pathogens in the hospital.^{1,2} Candidemia is associated with 40%–80% overall mortality, 5%–70% attributable mortality, prolongation of hospital stay, and substantial hospital costs.^{3–6} Azole prophylaxis in high-risk patients resulted in a decreasing incidence of candidemia in some hospitals.⁷ A concomitant emergence of non-*albicans* *Candida* spp. with decreased susceptibility or intrinsic resistance to fluconazole, in particular *Candida krusei* and *Candida glabrata*, has been described. This shift has been reported in breakthrough candidemia (BTC) occurring on fluconazole.^{8–17} A microbiological study in *Candida* isolates from BTC described a correlation between dose of fluconazole and minimal inhibitory concentration (MIC), without reporting related clinical data.¹⁸ In BTC, guidelines recommend the empirical change to an echinocandin or liposomal amphotericin B, regardless of the duration of fluconazole exposure.^{19–21} There is a need for more information on clinical and mycological characteristics of BTC and their impact on patients' management and outcome.

The objective of this nationwide prospective study from the Fungal Infection Network of Switzerland (FUNGINOS) was to characterize the patients at risk of BTC, the relationship between antifungal exposure, *Candida* spp. and antifungal susceptibility as well as the clinical severity and outcome of BTC.

Methods

Patients

Consecutive episodes of candidemia were prospectively studied over a three-year period (2004–2006) in universities ($n = 5$) and university-affiliated centers ($n = 20$) of the FUNGINOS network covering hospital care for 85% of the Swiss population. First episodes of candidemia were analyzed; relapsing or recurrent episodes were excluded.

Patients with candidemia were prospectively identified by microbiology laboratory investigators. Clinical investigators collected data on patients' demographics, risk factors, management, and outcome in a paper print report form. Data were centralized to the national study coordination. After queries to investigators, the final clinical reports were validated by the FUNGINOS data review committee (members listed in the section "Authors' contributions").

BTC was defined as candidemia occurring during or up to 48 hours after stopping antifungal prophylaxis or treatment of a duration of at least three days.¹⁸

The study has been approved by the Ethical Committee of the Lausanne University Hospital as the national coordinating center.

Candida bloodstream isolates

The microbiology laboratories of the 25 centers used automated blood culture systems (Bactec™ [Becton Dickinson, Sparks, Maryland, USA] or Bact/Alert® [bioMérieux, Marcy l'Etoile, France]). The *Candida* bloodstream isolates were centralized to the FUNGINOS mycological reference laboratory (Institute of Microbiology, Lausanne University Hospital). *Candida* species were identified by

standard biochemical assays in a test gallery (ATB ID 32 C®, bioMérieux, Marcy l'Etoile, France).²² In case of discordant species identification between center and reference laboratory, molecular identification was performed by PCR amplification and sequencing of the D1/D2 region of the large subunit of the 28S ribosomal RNA gene (28S rDNA). Antifungal susceptibility testing was performed by microtiter broth dilution method with the Sensititre® YeastOne™ test panel (TREK Diagnostic System, Cleveland, Ohio, USA). Minimal inhibitory concentrations (MIC) were interpreted according to clinical breakpoints recommended by the Clinical and Laboratory Standards Institute (CLSI).²³ *Candida* isolates with MIC fulfilling CLSI criteria for dose-dependent susceptibility and resistance were considered as non-susceptible.

Data analysis

The analysis was designed according to the guidelines from the Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement.²⁴

Data were analyzed using the SPSS 17.0 statistical software package (SPSS Inc., Chicago, IL, USA). Categorical data were compared by Chi-square or Fisher's exact test, and continuous variables by t-test or Mann–Whitney test. Uni- and multivariate logistic regression analyses were performed to assess the association of clinical variables with the occurrence of BTC. All variables with a p -value < 0.2 in the univariate analysis were included in a multivariate logistic regression model using a step-wise forward likelihood ratio procedure, which implies that only variables significantly associated with BTC remained in the final multivariate model. Collinearity of variables in the final model was estimated using the variance inflation factor: a value < 2 was considered as reflecting the absence of significant collinearity. Point estimates were reported as odds ratios (OR) with 95% confidence intervals (95%CI). A two-sided p -value < 0.05 was considered statistically significant.

Results

567 consecutive episodes of candidemia were reported. Forty-three episodes (8%) fulfilled the pre-defined criteria for breakthrough candidemia (BTC), while 524 (92%) did not (non-BTC). 550 (97%) *Candida* blood isolates were sent to the FUNGINOS reference mycology laboratory.

Among 43 BTC episodes, 37 (86%) occurred on fluconazole and 6 (14%) on another antifungal (3 voriconazole, 2 caspofungin, 1 itraconazole).

Patients' demographics and clinical characteristics in BTC and non-BTC are summarized in Table 1. Multivariate analysis identified independent associations of gastrointestinal (GI)-tract mucositis, acute gastrointestinal GvHD, immunosuppressive drugs, and total parenteral nutrition with BTC.

The proportions of *Candida* spp. in BTC vs. non-BTC are summarized in Table 2.

After detection of BTC, 46% of patients were treated with fluconazole and 54% with another antifungal drug, while in non-BTC, 85% of patients received fluconazole and 15% an alternative regimen ($p < 0.001$).

Table 1Uni- and multivariate analyses of demographic and clinical characteristics^a associated with breakthrough candidemia.

	BTC (n = 43)	Non-BTC (n = 524)	Univariate			Multivariate		
			OR	95%CI	p-value	OR	95%CI	p-value
Age, median years (range)	51 (0–85)	62 (0–97)			0.01 ^c			
Female gender	24 (56%)	220 (42%)	1.75	0.93–3.27	0.08 ^c			
Stay in intensive care unit	16 (37%)	162 (31%)	1.32	0.69–2.53	0.39			
Cancer	22 (51%)	191 (36%)			<0.001 ^c			
Hematological malignancy	14 (64%)	38 (20%)	6.00	2.82–12.79	<0.001 ^c			
Solid tumor	8 (36%)	153 (80%)	0.82	0.36–1.90	0.65			
Chemotherapy	16 (37%)	62 (12%)	4.42	2.25–8.65	<0.001 ^c			
Neutropenia (<0.5 G/L)	16 (37%)	37 (7%)	7.80	3.86–15.75	<0.001 ^c			
Gastrointestinal mucositis	14 (33%)	27 (5%)	8.89	4.21–18.74	<0.001^c	5.25	2.23–12.40	<0.001
Acute gastrointestinal GvHD	6 (14%)	1 (0.20%)	28.16	6.77–117.15	<0.001^c	6.25	1.00–38.87	0.05
Immunosuppressive drugs^b	32 (74%)	41 (8%)	4.39	2.21–8.71	<0.001^c	2.42	1.03–5.68	0.043
Central venous catheter	41 (95%)	437 (83%)	0.03	1.05–18.61	0.03 ^c			
Total parenteral nutrition	27 (63%)	188 (36%)	3.02	1.59–5.74	<0.001^c	2.87	1.44–5.71	0.003
Antacids	33 (78%)	355 (68%)	1.57	0.76–3.26	0.22			
Antibacterial therapy	41 (95%)	442 (84%)	3.80	0.90–16.03	0.05 ^c			
Renal failure	6 (14%)	101 (19%)	0.68	0.28–1.65	0.39			
Diabetes mellitus	6 (14%)	71 (14%)	1.04	0.42–2.54	0.94			

Items in bold are the variables included in the final multivariate model according to step-wise forward modeling and significantly associated with BTC.

^a At the time of candidemia.^b Immunosuppressive drugs: steroids (>20 mg prednisone-equivalent/day during >10 days), cyclosporine, tacrolimus, mycophenolate, azathioprine, methotrexate, and anti-thymocyte globulin.^c Characteristic included in the multivariate logistic regression model using a step-wise forward likelihood ratio procedure. No significant collinearity of the variables included in the final model was observed (variance inflation factor <2).

BTC, breakthrough candidemia; non-BTC, non-breakthrough candidemia; GvHD, graft-versus-host-disease.

Table 2*Candida* species distribution comparing breakthrough (BTC) and non-breakthrough candidemia (non-BTC).

	Breakthrough candidemia (n = 43)	Non-breakthrough candidemia (n = 507)
<i>C. albicans</i> ^a	18 (42%)	329 (65%)
Non- <i>albicans Candida</i> spp. ^a	25 (58%)	178 (35%)
<i>C. glabrata</i>	9 (19%)	94 (18%)
<i>C. tropicalis</i>	1 (2%)	32 (6%)
<i>C. parapsilosis</i>	3 (7%)	32 (5%)
<i>C. krusei</i>	5 (12%)	8 (2%)
Other <i>Candida</i> species	2 (9%)	30 (6%)

^a Comparing BTC with non-BTC, the proportions of *C. albicans* (42%, vs. 65%, respectively) and non-*albicans Candida* spp. (58% vs. 35%) were significantly different (p = 0.005).

Severe sepsis or septic shock was reported in 21% of BTC episodes vs. 23% of non-BTC (p = 0.85). 34% of patients with BTC died vs. 32% with non-BTC (p = 0.73).

Thirty-seven BTC episodes occurred on fluconazole (76% prophylaxis, 24% therapy). The median duration of fluconazole exposure was 11.5 days (3–62) in prophylaxis vs. 5 days (4–17) in therapy (p = 0.008). The median daily dose of fluconazole prophylaxis was 200 mg (50–800) and the median cumulative dose was 2,900 mg (600–21,600).

14/37 (38%) *Candida* spp. were non-susceptible to fluconazole (dose-dependent susceptible or resistant): 13/14 (93%) were isolated during fluconazole prophylaxis. The rate of fluconazole non-susceptibility increased with the duration of fluconazole exposure (Fig. 1, Panel A). A fluconazole exposure during 10 days or longer occurred in 43% of BTC and predicted a fluconazole non-susceptible *Candida* isolate with 71% sensitivity, 74% specificity, 63% positive predictive value (PPV), 82% negative predictive value (NPV), and 73% accuracy (ROC curve Fig. 1, Panel B). BTC occurring on fluconazole during more than 10 days was more often caused by non-*albicans Candida* spp. when compared with a shorter exposure (13/16, 81% vs. 6/21, 29%; OR 10.90, 95%CI 2.25–52.20, p = 0.001) (Fig. 2). Among 16 BTC episodes after prolonged fluconazole exposure, 10 (63%; 5

C. glabrata, 4 *C. krusei*, 1 *C. norvegensis*) were non-susceptible, whereas among 21 after shorter exposure, 4 (19%; 4 *C. glabrata*) were non-susceptible (OR 7.10, 95%CI 1.60–31.30, p = 0.007). The median MIC of fluconazole in BTC isolates was 4 mg/l (range 0.125–128) when exposure exceeded 10 days vs. 0.25 mg/l (range 0.125–32) after shorter exposure (p < 0.001).

7/23 patients with fluconazole susceptible BTC died (overall mortality 30%) vs. 5/14 patients with fluconazole non-susceptible BTC (36%, p = 1.00), respectively. Fluconazole was continued during more than three days in 9/14 (64%) BTC episodes due to non-susceptible isolates and switched to an appropriate antifungal regimen within three days in 5/14 (36%); overall mortality was 56% (5/9) and 0% (0/5), respectively (p = 0.085).

Discussion

This FUNGINOS study was designed on a large prospective sample of candidemias representing the nationwide epidemiology in Switzerland. Its unique characteristic was the integration of validated individual clinical and drug dosing data with mycological data from the national FUNGINOS reference laboratory. BTC due to non-susceptible non-*albicans Candida* spp. occurred in three out of four cases in hematological patients with toxic damage of the GI-tract receiving prolonged low-dose fluconazole prophylaxis. This observation from a robust clinical and mycological dataset provides a proof of principle of what has been described in previous reports focused on either clinical or mycological data. Implications of this finding for antifungal stewardship are: i) regular reassessment of the indication and duration of fluconazole prophylaxis for reducing the emergence of difficult to treat breakthrough infections requiring expensive parenteral regimens, ii) once species and antifungal susceptibility are known, de-escalation from empirical therapy for BTC is possible in a majority of patients with short fluconazole pre-exposure.

FUNGINOS observed BTC in 8% of 567 consecutive candidemias which occurred in an unselected hospital patient population from 25 hospitals. A retrospective survey of 409 candidemias from 6 hospitals reported 9% of BTC.¹⁵ The CANDIPOP investigators reported 15% of BTC among 237 candidemias in cancer patients.¹⁷ A




Fig. 1. Panel A. Duration of fluconazole exposure at the time of breakthrough candidemia and rate of non-susceptible *Candida* isolates. Thirty-seven episodes of breakthrough candidemia occurred during fluconazole prophylaxis or therapy.

Panel B. Duration of Fluconazole exposure at the time of breakthrough candidemia as predictor of non-susceptible *Candida* isolates.

retrospective study in surgical patients with intra-abdominal infections reported 15% of BTC.¹⁶ Other authors observed higher BTC proportions, up to 72% in hemato-oncological patients.^{10,15,25} Different case-mix and prophylaxis policies explain this large variability in the incidence of BTC.

In the FUNGINOS study 76% of BTC occurred on fluconazole prophylaxis, while rates in other surveys ranged 57%–100%.^{15–17} GI-tract mucositis following cytotoxic chemotherapy, acute gastrointestinal GvHD, immunosuppression, and total parenteral nutrition were found to be independently associated with BTC.^{15,17,26–29} Candidemia occurs in hemato-oncological patients after disruption of the intestinal mucosal barrier and invasion by *Candida* spp.

colonizing the GI-tract.^{30,31} Fluconazole prophylaxis is recommended in this high-risk setting, which explains the association of these conditions with BTC.³²

Our study offers a proof of principle by reporting the clinical-microbiological relationship between prolonged low-dose fluconazole prophylaxis in high-risk hemato-oncological patients with toxic damage of the GI-tract and occurrence of BTC due to non-susceptible non-*albicans* *Candida* spp. The selective pressure exerted on the endogenous flora highlights the importance of a regular reassessment of the duration of fluconazole prophylaxis for reducing the emergence of difficult to treat BTC. Other studies reported 40%–48% of non-susceptible *Candida* spp. in BTC, without providing dosing




Fig. 2. Proportions of isolated *Candida* spp. according to the duration of fluconazole exposure at the time of breakthrough candidemia (BTC). Non-albicans *Candida* spp. were more frequently isolated after fluconazole exposure exceeding 10 days ($p = 0.001$).

information.^{15,17} *C. krusei* and *C. glabrata* candidemia was observed in hemato-oncological patients on fluconazole prophylaxis, whose duration was not described.^{33–35} A mycological report by Pfaller et al. reported an association of fluconazole exposure with non-susceptible candidemia.³⁶ High fluconazole MICs were observed in non-albicans *Candida* spp. from BTC.^{25,37,38} Other reports did not associate fluconazole prophylaxis with a shift in the *Candida* species: different epidemiological and clinical settings might explain these contrasting results.^{39–41} A report by Clancy et al. from U.S. hospitals correlated fluconazole doses (>200 mg/d, >2000 mg cumulative) with dose-dependent susceptible or resistant BTC, without related clinical data.¹⁸

Rates of severe sepsis/septic shock (around 20%) and overall mortality (around 30%) did not differ in BTC and non-BTC. Data from the literature range 10%–80% and 30%–60%, respectively.^{15–17,25,27} Fluconazole susceptibility did not impact on mortality in BTC.^{32,37} While empirical antifungals other than fluconazole were more frequently prescribed in BTC, a trend to higher mortality was observed in patients with fluconazole non-susceptible BTC who were not promptly switched to an alternative regimen. Other authors recorded a reduced survival in patients with fluconazole-resistant BTC.^{4,17,38} Despite variability in case-mix and clinical practices, these observations suggest that a strict application of guidelines recommending empirical switch to an alternative antifungal therapy improves outcome in BTC. The small number of BTC episodes is a limitation which might have resulted in underpowered statistical analyses. Recent multicenter epidemiological surveys from Europe, South and North America, analyzed similar sample sizes of BTC: the consistency of our findings with previous reports corroborates their robustness.^{15,17,29,32,37,38} Although the validity of data collected in 2004–2006 might be debated, FUNGINOS showed that *Candida* species distribution and antifungal susceptibility remained stable over a 20-year period (Marchetti et al.,¹ Orasch et al.,⁴² and unpublished analyses from the FUNGINOS candidemia database). Based on this epidemiology, our analysis was designed in a unique, carefully validated, clinical and mycological dataset prospectively collected nationwide over a three-year period. In Switzerland, the

increase of the use of echinocandins during the following decade was moderate, and fluconazole remains the first-line agent for antifungal prophylaxis and by far the most frequently prescribed antifungal (unpublished analyses from the FUNGINOS candidemia database). Altogether these points support that the study findings are representative of the current epidemiology of BTC in Switzerland.

In conclusion, severity and outcome of BTC and non-BTC were not different. Prolonged low-dose fluconazole prophylaxis in hemato-oncological patients with toxic damage of the GI-tract was associated with BTC due to azole non-susceptible non-albicans *Candida* spp. This finding implies a regular reassessment of the duration of prophylaxis. Once species and MICs are known, a de-escalation from empirical antifungal therapy for BTC is possible in the majority of patients with short fluconazole pre-exposure.

Acknowledgments

Acknowledgments for financial support

The Fungal Infection Network of Switzerland Foundation (FUNGINOS) received unrestricted grant support from (in alphabetical order): Essex Schering-Plough, Gilead, Merck, Merck Sharp and Dohme, Novartis, and Pfizer. None of the above funding sources has been involved in study design and conduct, patient recruitment, data collection, analysis, and interpretation; writing of the article; or decision to submit the article for publication.

O.M. was supported by the Leenaards Foundation. In addition, the present project received unrestricted grant support from the Foundation for the Advancement in Medical Microbiology and Infectious Diseases (FAMMID), Lausanne, Switzerland. O.M. is a participant in the European Union's Seventh Framework Program (FP7/2007–2013) under grant agreement number HEALTH-2010-260338 (ALLFUN).

D.M. is a recipient of a Research Early Career Award from Hamilton Health Sciences Foundation (Jack Hirsh Fellowship).

All other co-authors declare no financial disclosure.

Acknowledgments for logistic and technical support

The authors and the FUNGINOS Group warmly thank Mrs. Isabel Cobos, Mrs. Aurélie Guillet, Mrs. Corine Guyaz, Mrs. Monika Ochsner, and Mrs. Annie Savoie of the Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, for outstanding assistance in collecting and managing clinical data from candidemia patients as well as Mr. Christian Durussel, Mrs. Dominique Pilloud, Dr. Philippe Hauser, and colleagues for outstanding technical support in collecting *Candida* bloodstream isolates and performing species identification and antifungal susceptibility testing at the FUNGINOS reference mycology laboratory, Institute of Microbiology, Lausanne University Hospital.

Authors' contributions

O.M. designed, implemented, and coordinated the candidemia cohort study.

J.G., S.Z., A.I., K.B., U.F., C.O., A.C., T.Bre., and O.M. collected clinical data, together with the clinical investigators from the centers of the FUNGINOS network listed in the Appendix.

J.S., K.M., R.Z., T.Bru., R.F., and J.B. collected *Candida* blood isolates and performed species identification and antifungal susceptibility testing, together with the clinical microbiologists from the centers of the FUNGINOS network listed in the Appendix.

J.B. and F.L. coordinated the FUNGINOS reference mycology laboratory.

O.M. coordinated the Data Review Committee composed of K.B., T.Bre., U.F., J.G., A.I., and S.Z.

C.O., D.M., J.B. and O.M. organized the dataset and performed statistical analyses.

C.O., D.M., J.B. and O.M. wrote the manuscript, with the help of S.Z., L.D., N.K., A.C., V.E., P.Y.B., T.C., F.L., S.E., C.V.D., C.R., and J.F.

All authors critically revised the manuscript and accepted the final version submitted for publication.

Appendix

Fungal Infection Network of Switzerland (FUNGINOS): Investigators of the Candidemia Study

Clinical Investigators (institutions and persons in alphabetical order):

Thomas Bregenzer, Anna Conen, Kantonsspital, Aarau.
 Anna Conen, Ursula Flückiger, Nina Khanna, Christina Orasch, University Hospital, Basel.
 Ulrich Heininger, Universitätskinderhospital, Basel.
 Mario Francioli, Ospedale San Giovanni, Ente Ospedaliero Cantonale, Bellinzona. Lauro Damonti, Stefan Zimmerli, University Hospital, Bern.
 Madeleine Rothen, Claudine Zellweger, Spitalzentrum, Biel.
 Madeleine Rothen, Philipp Tarr, Kantonsspital, Bruderholz.
 Felix Fleisch, Kantonsspital, Chur.
 Christian Chuard, Véronique Erard, Hôpital Cantonal, Fribourg.
 Stéphane Emonet, Jorge Garbino, Christian van Delden, University Hospital, Geneva.
 Daniel Genne, Hôpital Communal, La-Chaux-de-Fonds.
 Pierre-Yves Bochud, Thierry Calandra, Lauro Damonti, Véronique Erard, Frédéric Lamoth, Oscar Marchetti, Christina Orasch, University Hospital, Lausanne.
 Jean-Philippe Chave, Clinique Bois-Cerf, Clinique Cécil, and Clinique La Source, Lausanne.
 Peter Graber, Kantonsspital, Liestal.
 Rita Monotti, Ospedale Regionale, Ente Ospedaliero Cantonale, Locarno.

Enos Bernasconi, Ospedale Civico, Ente Ospedaliero Cantonale, Lugano.
 Marco Rossi, Kantonsspital, Luzern.
 Martin Krause, Kantonsspital, Münsterlingen.
 Rein-Jan Piso, Kantonsspital, Olten.
 Frank Bally, Nicolas Troillet, Institut Central des Hôpitaux Valaisans, Sion.
 Katia Boggian, Kantonsspital, Sankt Gallen.
 Gerhard Eich, Jacques Gubler, Kantonsspital, Winterthur.
 Jan Fehr, Alexander Imhof, Christian Ruff, University Hospital, Zürich.
 Gerhard Eich, Jacques Gubler, Stadtsptial Triemli, Zürich.
 Christoph Berger, Universitätskinderhospital, Zürich.

Microbiology Laboratory Investigators (institutions and persons in alphabetical order):

Hans Fankhauser, Ivo Heinzer, Kantonsspital, Aarau.
 Reno Frei, University Hospital, Basel.
 Roland Hertel, Universitätskinderhospital, Basel.
 Marisa Dolina, Orlando Petrini, Istituto Cantonale di Microbiologia, Bellinzona.
 Olivier Dubuis, Viollier Microbiology Laboratories, Bienne.
 Konrad Mühlethaler, University Hospital, Bern.
 Suzanne Graf, Kantonsspital, Bruderholz and Kantonsspital, Liestal.
 Martin Risch, Eva Ritzler, Kantonsspital, Chur.
 Dominique Fracheboud, Hôpital Cantonal, Fribourg.
 Peter Rohner, Jacques Schrenzel, University Hospital, Geneva.
 Reto Lienhardt, Hôpital Communal, La-Chaux-de-Fonds.
 Jacques Bille, Frédéric Lamoth, University Hospital, Lausanne.
 Corinne Andreutti-Zaugg, Alberto Gallusser, Clinique La Source, Lausanne.
 Suzanne Graf, Kantonsspital, Liestal.
 Gaby Pfyffer, Kantonsspital, Luzern.
 Karin Herzog, Kantonsspital, Münsterlingen.
 Urs Schibli, Kantonsspital, Olten.
 Lysiane Tissière, Institut Central des Hôpitaux Valaisans, Sion.
 Thomas Bruderer, Detlev Schultze, Kantonsspital, Sankt Gallen.
 Reinhard Zbinden, University Hospital, Zürich.

References

- Marchetti O, Bille J, Flückiger U, Eggimann P, Ruff C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. *Clin Infect Dis* 2004;38(3):311–20.
- Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis* 2004;39(3):309–17.
- Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. *Clin Infect Dis* 2005;41(9):1232–9.
- Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. *Clin Infect Dis* 2009;48(12):1695–703.
- Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. *Infect Control Hosp Epidemiol* 2005;26(6):540–7.
- Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. *Crit Rev Microbiol* 2010;36(1):1–53.
- Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. *J Infect Dis* 2000;181(1):309–16.
- Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. *Candida* bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. *Antimicrob Agents Chemother* 2011;55(2):561–6.
- Sampaio Camargo TZ, Marra AR, Silva CV, Cardoso MF, Martino MD, Camargo LF, et al. Secular trends of candidemia in a tertiary care hospital. *Am J Infect Control* 2010;38(7):546–51.

10. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. *Cancer* 2009;115(20):4745–52.
11. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-*Candida albicans* candidaemia and the association of *Candida krusei* with fluconazole use. *J Hosp Infect* 2002;50(1):56–65.
12. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. *Haematologica* 2006;91(8):1068–75.
13. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. *Candida glabrata* and *Candida krusei* fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. *Bone Marrow Transplant* 2001;28(9):873–8.
14. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of *Torulopsis glabrata* infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. *Antimicrob Agents Chemother* 1993;37(9):1847–9.
15. Cuervo G, Garcia-Vidal C, Nucci M, Puchades F, Fernandez-Ruiz M, Obed M, et al. Breakthrough candidaemia in the era of broad-spectrum antifungal therapies. *Clin Microbiol Infect* 2016;22(2):181–8.
16. Zilberberg M, Yu HT, Chaudhari P, Emons MF, Khandelwal N, Shorr AF. Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study. *Crit Care* 2014;18(5):590.
17. Puig-Asensio M, Ruiz-Camps I, Fernandez-Ruiz M, Aguado JM, Munoz P, Valerio M, et al. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. *Clin Microbiol Infect* 2015;21(5):491.e1–10.
18. Clancy CJ, Staley B, Nguyen MH. In vitro susceptibility of breakthrough *Candida* bloodstream isolates correlates with daily and cumulative doses of fluconazole. *Antimicrob Agents Chemother* 2006;50(10):3496–8.
19. EUCAST technical note on fluconazole. *Clin Microbiol Infect* 2008;14(2):193–5.
20. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikian-Akdagli S, et al. ESCMID* guideline for the diagnosis and management of *Candida* diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). *Clin Microbiol Infect* 2012;18(Suppl 7):53–67.
21. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016;62(4):e1–50.
22. Warren HBHK, editor. *Candida, Cryptococcus, and other yeasts of medical importance*. Washington DC: ASM Press; 2008.
23. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth international supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012. p. 32.
24. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370(9596):1453–7.
25. Colombo AL, Nucci M, Park BJ, Nouer SA, Arthington-Skaggs B, da Matta DA, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. *J Clin Microbiol* 2006;44(8):2816–23.
26. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. *Clin Infect Dis* 2001;33(2):177–86.
27. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. *Clin Infect Dis* 1992;15(3):414–21.
28. Sallah S, Wan JY, Nguyen NP, Vos P, Sigounas G. Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study. *Cancer* 2001;92(6):1349–53.
29. Pasqualotto AC, Nedel WL, Machado TS, Severo LC. Risk factors and outcome for nosocomial breakthrough candidaemia. *J Infect* 2006;52(3):216–22.
30. Koh AY, Kohler JR, Cogshall KT, Van Rooijen N, Pier GB. Mucosal damage and neutropenia are required for *Candida albicans* dissemination. *PLoS Pathog* 2008;4(2):e35.
31. Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. *Clin Infect Dis* 1996;22(Suppl 2):S73–88.
32. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. *Clin Infect Dis* 2001;32(12):1713–7.
33. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in *Candida krusei* infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. *N Engl J Med* 1991;325(18):1274–7.
34. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de Pipaon M, Hernandez-Caballero C, Aznar-Martin J, et al. Risk factors for fluconazole-resistant candidemia. *Antimicrob Agents Chemother* 2010;54(8):3149–54.
35. Munoz P, Sanchez-Somolinos M, Alcalá L, Rodriguez-Creixems M, Peláez T, Bouza E. *Candida krusei* fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. *J Antimicrob Chemother* 2005;55(2):188–93.
36. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of *Candida* species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. *J Clin Microbiol* 2010;48(4):1366–77.
37. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. *Antimicrob Agents Chemother* 2011;55(2):532–8.
38. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. *J Antimicrob Chemother* 2010;65(5):1042–51.
39. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of *Candida* spp. and *Cryptococcus neoformans* collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. *Diagn Microbiol Infect Dis* 2004;48(3):201–5.
40. Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramou P, et al. Prior antimicrobial therapy and risk for hospital-acquired *Candida glabrata* and *Candida krusei* fungemia: a case-case-control study. *Antimicrob Agents Chemother* 2005;49(11):4555–60.
41. Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is *Candida* speciation predictive of the susceptibility pattern? *J Antimicrob Chemother* 2010;65(7):1460–5.
42. Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Muhlethaler K, et al. *Candida* species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. *Clin Microbiol Infect* 2014;20(7):698–705.